• Policy
• The severity level of COVID-19 lowered from May
• by Lee, Jeong-Hwan Mar 31, 2023 06:09am

• Policy
• Cold drugs subject to PVA will be adjusted
• by Lee, Tak-Sun Mar 31, 2023 06:08am

• Policy
• Overseas clinical trial drugs for therapeutic purposes
• by Lee, Hye-Kyung Mar 31, 2023 06:08am

• Policy
• Started a demand survey for drugs participating in the pilot
• by Lee, Tak-Sun Mar 31, 2023 06:08am

• Policy
• About 180 clinics without IRB used diagnostic drugs
• by Park,Yang-myeong Mar 30, 2023 05:42am

• Policy
• New Pompe disease drug Nexviazyme is approved in Korea
• by Lee, Hye-Kyung Mar 30, 2023 05:41am

• Policy
• Obizur will be evaluated for reimbursement upon approval
• by Lee, Tak-Sun Mar 30, 2023 05:41am

• Policy
• Govt seeks to improve the drug price reduction system
• by Lee, Tak-Sun Mar 29, 2023 06:02am

• Policy
• 87.5% of anticancer/rare drugs, evaluated as drugs w/o PE
• by Lee, Tak-Sun Mar 29, 2023 06:01am

• Policy
• Erleada is listed
• by Lee, Tak-Sun Mar 28, 2023 05:56am